key: cord-0289682-e8gzl3tb
authors: Syed-Abdul, S.; Babu, A. S.; Bellamkonda, R. S.; Itumalla, R.; Acharyulu, G.; Krishnamurthy, S.; Ramana, Y. V. S.; Mogilicharla, N.; Malwade, S.; Li, Y.-C.
title: Using Artificial Intelligence-based models to predict the risk of Mucormycosis among COVID-19 Survivors: An Experience from India
date: 2021-09-16
journal: nan
DOI: 10.1101/2021.09.13.21263511
sha: f5b2d18ee46a992acbbdcc5445f8a085750a331d
doc_id: 289682
cord_uid: e8gzl3tb

Introduction: India reported a severe public health challenge not only due to the COVID-19 outbreak but also the increasing number of associated mucormycosis cases since 2021. This study aimed at developing artificial intelligence-based models to predict the risk of mucormycosis among the patients at the time of discharge from the hospital. Methods: The dataset included 1229 COVID-19 positive patients, and additional 214 inpatients, COVID-19 positive as well as infected with mucormycosis. We used logistic regression, decision tree, and random forest, and the extreme gradient boosting algorithm. All our models were evaluated with 5-fold validation to derive a reliable estimate of the model error. Results: The logistic regression, XGBoost, and random forest performed equally well with AUROC 95.0, 94.0, and 94.0 respectively. This study also determined the top five variables namely obesity, anosmia, de novo diabetes, myalgia, and nasal discharge, which showed a positive impact on the risk of mucormycosis. Conclusion: The developed model has the potential to predict the patients at high risk and thus, consequently initiating preventive care or aiding in early detection of mucormycosis infection. Thus, this study holds potential for early treatment and better management of patients suffering from COVID-19 associated mucormycosis.

Mucormycosis (previously called zygomycosis) is a life-threatening but rare fungal infection caused by a group of molds called mucormycetes [1] . It is an opportunistic infection characterized by sinusitis and orbital cellulitis that penetrates the arteries to produce thrombosis of the ophthalmic and internal carotid arteries, and later invades the veins and lymphatics [2] . India, the second most populated country in the world has been facing public health challenge due to the outbreak of the COVID-19 [3] . As of July 8th 2021, in India 4,60,704 active COVID-19 cases and 4,05,028 deaths were reported [4] . At this crucial juncture, increasing number of the mucormycosis cases in country are alarming the policy makers and healthcare experts emphasizing the great necessity of preventive measures to detect and treat the patients with mucormycosis. Until 28 th June 2021, India reported 40,845 cases of mucormycosis, and considering hundreds of thousands of COVID-19 active cases this number is expected to increase significantly. As of 21 st July, 2021, India recorded more than 4300 deaths from COVID-19 related mucormycosis [5] . Difficult diagnosis and relapse of the disease are among the factors hampering treatment success. Therefore, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263511 doi: medRxiv preprint this study is aimed to develop artificial intelligence (AI)-based models to predict the risk of mucormycosis among the COVID-19 patients at the time of their discharge from hospital.

This single-center retrospective study was conducted at a tertiary public hospital, designated for COVID-19 and mucormycosis treatment at the Telangana state in India. The dataset comprised of 1229 COVID-19 positive patients, and additional 214 inpatients, those who were tested positive for COVID-19 and subsequently infected with mucormycosis. All these patients were hospitalized and received treatment between 19th March, 2021 and 30th June 2021. Since the patient group with mucormycosis included only those in the age group between 30 to 75 years, we filtered all the patients in the dataset to that age group to ensure that the models are unbiased. The original dataset from medical records contains 74 features from which relevant variables were filtered and encoded for predictive modeling. The categorical variables were binary/one-hot encoded. After encoding, 35 features were input to our prediction models. The final set of features used for modeling is as below:

• Nominal features: 

We used logistic regression, decision tree and random forest from the scikit-learn [6] 5 library and the extreme gradient boosting algorithm from the XGBoost [7] library. To prevent overfitting and selection bias from our skewed dataset we tuned the models to generalize well on unseen data.

Regularization was adapted (L2 for logistic regression and XGBoost), wherever applicable and the model parameters were chosen to reduce the model complexity (limiting the depth of the trees to 5, reducing XGBoost to 100 trees and increasing the forest to 500 trees). We used class weights in all our models to handle the class imbalance. We evaluated all our models with 5-fold validation to derive a reliable estimate of the model error.

The AUROC, recall, precision and accuracy from the different models used with the 5-fold validation are shown in figure 1 . The logistic regression, XGBoost and random forest performed equally well with AUROC 95.0, 94.0, and 94.0 respectively. The best accuracy and precision . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263511 doi: medRxiv preprint (PPV) were 0.91 ± 0.026 and 0.67 ± 0.0526, respectively achieved by XGBoost, followed by logistic regression. Figure 2 shows box plot of coefficients for all the features across the 5 folds indicating variables having positive and negative impact on the risk of mucormycosis. that uncontrolled diabetes can be a strong pre-disposing factor for post COVID mucormycosis [8] [9] [10] . Some studies also pointed out other risk factors for mucormycosis, such as treatment with corticosteroids, those who underwent organ transplantation, or those suffering from hematological malignancies [11] [8] [12]. Our study was the first one to reveal de novo diabetes obesity, anosmia, . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted September 16, 2021. ; https://doi.org/10.1101/2021.09.13.21263511 doi: medRxiv preprint

Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report

Mucormycosis-a new disease

India's Response to COVID-19 Crisis. The Indian Economic Journal. of India COVID-19 Cases across India 2021

BBC News Mucormycosis: India records more than 4,300 'black fungus' deaths 2021

Scikit-learn: Machine learning in Python. the Journal of machine Learning research

Xgboost: A scalable tree boosting system

Mucormycosis: An opportunistic pathogen during COVID-19

Associated Mucormycosis from a Tertiary Care Hospital in India: A Case Series

Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021. 11. Ibrahim AS